Alpine Immune Sciences competitors

Alpine Immune Sciences's competitors include Rich Pharmaceuticals, Syndax Pharmaceuticals, G1 Therapeutics and Rexahn Pharmaceuticals
Add company...
Alpine Immune Sciences
Modern therapies targeting the immune synapse.
Rich Pharmaceuticals
Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323, for the treatment of acute myelogenous leukemia in refractory patients.
Syndax Pharmaceuticals
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
G1 Therapeutics
G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
Founding Date
Founding Date
2015
Founding Date
N/A
Founding Date
2005
Founding Date
2008
Founding Date
2001
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Seattle, US HQ
Locations
Beverly Hills, US HQ
Locations
Waltham, US HQ
Locations
Durham, US HQ
Locations
Rockville, US HQ
Employees
Employees
N/A
Employees
1
Employees
3237% decrease
Employees
3827% increase
Employees
20
Valuation ($)
Valuation ($)
N/A
Valuation ($)
206.6 k
Valuation ($)
169.8 m
Valuation ($)
1.9 b
Valuation ($)
51.1 m
Twitter followers
Twitter followers
166
Twitter followers
N/A
Twitter followers
108
Twitter followers
N/A
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$1.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$2.1m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Net income
Net income
($7.8m) (FY, 2017)
Net income
N/A
Net income
($60.8m) (FY, 2017)
Net income
($60.1m) (FY, 2017)
Net income
($25.3m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 49.3m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 92.5m
Total funding raised
$ 5m
For sources of this data, please see the company profileDownload Excel

View company profiles

Rich Pharmaceuticals
HQ
Beverly Hills, US
Employees
1

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323, for the treatment of acute myelogenous leukemia in refractory patients.

View company
Syndax Pharmaceuticals
HQ
Waltham, US
Employees
32↓ 37% decrease

Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.

View company
G1 Therapeutics
HQ
Durham, US
Employees
38↑ 27% increase

G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.

View company
Rexahn Pharmaceuticals
HQ
Rockville, US
Employees
20

Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.

View company